GlassScriptPhysician profile
Mark H Amols
NPI 1528048006
$3,016.50
in general payments reported to CMS, 2019-2025
21 companies · $431 in 2025
The $431 reported for 2025 was more than what 85% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $21.59 · 2021: $226 · 2022: $180 · 2023: $488 · 2024: $790 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $521.89 | 2021-2025 | Follistim Aq, Pregnyl, Ganirelix Acetate |
| Emd Serono, INC. | $417.60 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $350.58 | 2019-2025 | Menopur |
| Hologic Sales and Service, LLC | $302.28 | 2019-2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Abbvie INC. | $225.05 | 2019-2022 | |
| Hamilton Thorne, INC. | $158.96 | 2025 | Lenshooke Semen Quality Analyzer, Cook, Guardia |
| Merck Sharp & Dohme LLC | $134.39 | 2019-2021 | |
| Roche Diagnostics Corporation | $127.18 | 2019-2023 | Cobas 4800 Ct/Ng Test V2.0 |
| Gynesonics, INC. | $124.99 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertex Pharmaceuticals Incorporated | $120.37 | 2025 | |
| Alexion Pharmaceuticals, INC. | $106.32 | 2019 | |
| Viiv Healthcare Company | $105.44 | 2023 | Apretude |
| Myriad Women'S Health, INC. | $105.11 | 2023 | Genesight |
| Galen US INC | $67.66 | 2019 | |
| Virtus Pharmaceuticals LLC | $34.01 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $31.69 | 2023 | |
| Myovant Sciences INC. | $19.09 | 2022 | |
| Agile Therapeutics, INC. | $17.03 | 2021 | |
| Covidien LP | $16.92 | 2019 | |
| Duchesnay USA Incorporated | $15.51 | 2019 | |
| Genzyme Corporation | $14.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Amols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.